Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.66 |
| ▸ | DRD1 | P21728 | 1/20 | 0.66 |
| ▸ | HTR1B | P28222 | 1/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9620015 | 0.99 | HTR1A (0.65) | HTR1ADRD2DRD1HTR1BHTR2A | |
| SCHEMBL9082977 | 0.94 | HTR1A (0.60) | HTR1ADRD2DRD1HTR1BHTR2A | |
| SCHEMBL9441673 | 0.92 | — | — | |
| SCHEMBL10613018 | 0.91 | — | — | |
| SCHEMBL9083448 | 0.91 | HTR1A (0.63) | HTR1ADRD2DRD1HTR1BHTR2A | |
| SCHEMBL9083462 | 0.90 | HTR1A (0.60) | HTR1ADRD2DRD1HTR1BHTR2A | |
| SCHEMBL8823806 | 0.90 | HTR1A (0.57) | HTR1ADRD2DRD1HTR1BHTR2A | |
| SCHEMBL9084563 | 0.89 | — | — | |
| SCHEMBL9456624 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL9619904 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9668995-B2 | Treatment of motor fluctuations | MOTAC NEUROSCIENCE LIMITED (GB) | 2017-06-06 | — | — | US | claimed |
| US-20110178178-A1 | Treatment of Motor Fluctuations | MOTAC NEUROSCIENCE LIMITED (GB) | 2011-07-21 | — | — | US | claimed |
| EP-1339398-B1 | TREATMENT OF MOTOR FLUCTUATIONS WITH 5-HYDROXYTRYPTAMINE 1A RECEPTOR ACTIVITY ENHANCING COMPOUNDS | MOTAC NEUROSCIENCE LTD (GB) | 2008-09-03 | — | — | EP | claimed |
| US-20040067956-A1 | Treatment of motor fluctuations | MOTAC NEUROSCIENCE LIMITED (GB) | 2004-04-08 | — | — | US | claimed |
| EP-1339398-A2 | TREATMENT OF MOTOR FLUCTUATIONS WITH 5-HYDROXYTRYPTAMINE 1A RECEPTOR ACTIVITY ENHANCING COMPOUNDS | Motac Neuroscience Limited (GB) | 2003-09-03 | — | — | EP | claimed |
| US-20020173511-A1 | Serotonergic compositions and methods for treatment of mild cognitive impairment | WURTMAN RICHARD J (US) | 2002-11-21 | — | — | US | claimed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | claimed |
| WO-2002036107-A2 | TREATMENT OF MOTOR FLUCTUATIONS WITH 5-HYDROXYTRYPTAMINE 1A RECEPTOR ACTIVITY ENHANCING COUMPOUNDS | MOTAC NEUROSCIENCE LIMITED (GB) | 2002-05-10 | — | — | WO | claimed |
| US-4992465-A | Antidepressant, anxiolytic agents; treating central nervous system disorders | CIBA-GEIGY CORPORATION (US) | 1991-02-12 | — | — | US | claimed |
| US-9668995-B2 | Treatment of motor fluctuations | MOTAC NEUROSCIENCE LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| US-9034798-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-8569481-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110178178-A1 | Treatment of Motor Fluctuations | MOTAC NEUROSCIENCE LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | KOESTER HUBERT | 2011-05-19 | — | — | US | disclosed |
| US-4992465-A | Antidepressant, anxiolytic agents; treating central nervous system disorders | CIBA-GEIGY CORPORATION (US) | 1991-02-12 | — | — | US | disclosed |
| WO-1990012795-A1 | SUBSTITUTED 3-AMINO CHROMANS | THE UPJOHN COMPANY (US) | 1990-11-01 | — | — | WO | disclosed |
| US-4801605-A | ANTIDEPRESSANT, NERVOUS SYSTEM DISORDERS, SEROTONIC ANTAGONIST | CIBA-GEIGY CORPORATION (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0280269-A1 | 3-Amino-dihydro-[1]-benzopyrans and benzothiopyrans | CIBA-GEIGY AG (CH) | 1988-08-31 | — | — | EP | disclosed |
| EP-0279150-A1 | 5-Oxy-substituted-3-aminochroman compounds, processes for their preparation, pharmaceutical compositions containing them and methods of treatment therewith | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1988-08-24 | — | — | EP | disclosed |
| WO-1988004654-A1 | 5-HYDROXY-3-AMINOCHROMAN COMPOUNDS, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF TREATMENT THEREWITH | Astra Läkemedel Aktiebolag (SE) | 1988-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PTMS, QPCTL, SRMS | HTR1A 4611/4885DRD2 4030/4885DRD1 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.